NYSE: ABTAbbott Laboratories Stock
$105.27-0.63 (-0.59%)
Updated Apr 18, 2024
ABT Price
$105.27
Fair Value Price
N/A
Market Cap
$182.66B
52 Week Low
$89.67
52 Week High
$121.64
P/E
32.09x
P/B
4.7x
P/S
4.78x
PEG
1.38x
Dividend Yield
2.01%
Revenue
$40.11B
Earnings
$5.72B
Gross Margin
55.2%
Operating Margin
18.2%
Profit Margin
14.3%
Debt to Equity
0.89
Operating Cash Flow
$7B
Beta
0.8
Next Earnings
N/A
Ex-Dividend
Apr 12, 2024
Next Dividend
May 15, 2024
ABT Overview
Abbott Laboratories is a medical device and health care company. Its products include various medical devices, diagnostic tools and technologies, branded generic medicines, and nutritional products. Among its well-known brands are Pedialyte, Similac, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip. The company was founded in 1888 and is headquartered in Abbott Park, IL.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABT scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABT ($105.27) is trading above its intrinsic value of $44.61, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ABT is good value based on its earnings relative to its share price (32.09x), compared to the US market average (41.33x)
P/E vs Market Valuation
ABT is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more ABT due diligence checks available for Premium users.
Be the first to know about important ABT news, forecast changes, insider trades & much more!
ABT News
Valuation
ABT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
32.09x
Industry
28.61x
Market
41.33x
ABT is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ABT is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ABT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.7x
Industry
3.63x
ABT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABT price to earnings growth (PEG)
For valuing profitable companies with growth potential
ABT is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
ABT's financial health
Profit margin
Revenue
$10.2B
Net Income
$1.6B
Profit Margin
15.6%
ABT's Earnings (EBIT) of $7.30B... subscribe to Premium to read more.
Interest Coverage Financials
ABT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$73.2B
Liabilities
$34.4B
Debt to equity
0.89
ABT's short-term assets ($22.67B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABT's short-term assets ($22.67B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ABT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.0B
Investing
-$824.0M
Financing
-$2.1B
ABT's operating cash flow ($7.26B)... subscribe to Premium to read more.
Debt Coverage Financials
ABT vs Medical Device Stocks
Abbott Laboratories Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.